Board of Pharmacy by Putnam, C.
REGULATORY AGENCY ACTION
* LEGISLATION
The following is a status update on
bills reported in detail in CRLR Vol. 14,
Nos. 2 & 3 (Spring/Summer 1994) at pages
93-94:
SB 2036 (McCorquodale), as amended
August 26, creates a "sunset" review pro-
cess for occupational licensing boards
within DCA, requiring each to be compre-
hensively reviewed every four years. SB
2036 imposes an initial "sunset" date of
July 1, 1999 for the Board; creates a Joint
Legislative Sunset Review Committee
which will review the Board's perfor-
mance approximately one year prior to its
sunset date; and specifies I I categories of
criteria under which the Board's perfor-
mance will be evaluated. Following re-
view of the agency and a public hearing,
the Committee will make recommenda-
tions to the legislature on whether the
Board should be abolished, restructured,
or redirected in terms of its statutory au-
thority and priorities. The legislature may
then either allow the sunset date to pass (in
which case the Board would cease to exist
and its powers and duties would transfer
to DCA) or pass legislation extending the
sunset date for another four years. This bill
was signed by the Governor on September
26 (Chapter 908, Statutes of 1994).
AB 2943 (Hauser). Under existing law,
the Board is required to adopt regulations
requiring that licensees submit proof of
continuing education as a condition of
renewal of licensure. As amended June 29,
this bill authorizes the Board to adopt
regulations to require licensees to main-
tain current certification in cardiopulmo-
nary resuscitation. [14:2&3 CRLR 93;
12:2&3 CRLR 133] This bill was signed
by the Governor on September 15 (Chap-
ter 578, Statutes of 1994).
SB 1399 (Lewis), as amended April
13, authorizes the Board, notwithstanding
any other provision of law relating to op-
tometry, to issue a certificate of registra-
tion to persons licensed in another state
who meet certain other qualifications. This
bill was signed by the Governor on August
31 (Chapter 403, Statutes of 1994).
The following bills died in committee:
AB 2020 (Isenberg), which would have,
among other things, authorized optome-
trists to use specified diagnostic and ther-
apeutic pharmaceutical agents; AB 1894
(Polanco), which would have authorized
ancillary personnel who work under the
supervision of an optometrist to assist in
the preparation of the patient and the pre-
liminary collection of data that does not
require the exercise of professional judg-
ment or the skill of an optometrist; and SB
908 (Calderon), which would have pro-
vided that the terms "license" and "certif-
icate of registration" are deemed to be
synonymous for the purposes of the pro-
visions of law regarding the licensure and
regulation of optometry.
* LITIGATION
In compliance with the court's April 25
order in Engineers and Scientists of Cal-
ifornia (ESC), et al. v. Division of Allied
Health Professions, No. 532588 (Sacra-
mento County Superior Court), the Medi-
cal Board published an August 19 notice
in the California Regulatory Notice Reg-
ister stating that section 1366(b)(4), Title
16 of the CCR, is invalid in its entirety.
The section which permitted unlicensed
medical assistants to perform "automated
visual field testing, tonometry, or other
simple or automated ophthalmic testing"
under certain conditions, was invalidated
by the court due to procedural irregulari-
ties in the rulemaking process. [14:2&3
CRLR 94; 14:1 CRLR 72; 13:2&3 CRLR
100] At the Board's August meeting, Ex-
ecutive Officer Karen Ollinger noted that
the Medical Board plans to convene a
factfinding session including optometry
representatives before it redrafts that pro-
vision of its medical assistant regulations.
U RECENT MEETINGS
At its August 18-19 meeting, the Board
discussed IAB's creation of the Council
on Optometric Practitioner Education
(COPE), a centralized approval process
for optometric continuing education (CE)
courses. According to lAB, of which the
Board is a member, COPE serves as a
national clearinghouse for all CE courses
on a statewide, regional, or national scope,
and was created to eliminate duplicative
efforts to approve CE courses by state
boards, instructors, and program adminis-
trators. State boards do not have to pay a
fee to participate in COPE, as it is an IAB
service to its member state boards. At the
meeting, the Board reviewed the materials
provided by IAB explaining how COPE
reviews and approves CE courses, criteria
for course qualification, and criteria for
administrator qualification, among other
things. Following discussion, the Board
unanimously agreed to utilize COPE for
the approval of CE courses.
Also at the August meeting, the Board
agreed to meet on October 14 in Monterey
for a strategic planning meeting.
* FUTURE MEETINGS
October 14 in Monterey
(strategic planning session).
December 1-2 in San Diego.
BOARD OF PHARMACY
Executive Officer: Patricia Harris
(916) 445-5014
p ursuant to Business and Professions
Code section 4000 et seq., the Board
of Pharmacy grants licenses and permits
to pharmacists, pharmacies, drug manu-
facturers, wholesalers, and sellers of hy-
podermic needles. It regulates all sales of
dangerous drugs, controlled substances,
and poisons. The Board is authorized to
adopt regulations, which are codified in
Division 17, Title 16 of the California
Code of Regulations (CCR). To enforce its
regulations, the Board employs full-time
inspectors who investigate complaints re-
ceived by the Board. Investigations may
be conducted openly or covertly as the
situation demands.
The Board conducts fact-finding and
disciplinary hearings and is authorized by
law to suspend or revoke licenses or per-
mits for a variety of reasons, including
professional misconduct and any acts sub-
stantially related to the practice of phar-
macy.
The Board consists of ten members,
three of whom are nonlicensees. The re-
maining members are pharmacists, five of
whom must be active practitioners. All are
appointed for four-year terms.
In January 1994, public member Herb
Stoecklein resigned from the Board; at
this writing, he has not yet been replaced.
*MAJOR PROJECTS
Electronic Transmission of Pre-
scriptions. AB 1807 (Bronshvag) (Chap-
ter 26, Statutes of 1994) revised the defi-
nition of the term "prescription" to include
prescriptions for controlled substances
that are electronically transmitted; AB
1807 also amended Health and Safety
Code section 11167.5 to provide that an
order for a Schedule II controlled sub-
stance in a licensed skilled nursing facil-
ity, an intermediate care facility, or a li-
censed home health care agency providing
hospice care may be dispensed upon an
oral or electronically transmitted prescrip-
tion, subject to specified conditions.
114:2&3 CRLR 98]
At its May 25-26 meeting, the Board
reviewed draft regulatory language to im-
plement AB 1807. Among other things,
the proposed language would provide
that, except as otherwise prohibited by
law, prescriptions may be transmitted by
electronic means from the prescriber to the
pharmacy. An electronically transmitted
prescription order must include the name
and address of the prescriber, a phone
number for verbal confirmation, date of
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transmission, and the identity of the recip-
ient, as well as other information required
by state and federal law. An electronically
transmitted prescription shall be transmit-
ted only to the pharmacy of the patient's
choice; the pharmacy receiving the elec-
tronic transmission must either receive or
have the capacity to retrieve the prescrip-
tion in hard copy form. The regulatory
language also provides for an "interim
storage device," which is an electronic file
into which a prescription is entered for
later retrieval by an authorized individual;
any interim storage device shall, in addi-
tion to specified information, record and
maintain the date of entry and/or receipt
of the prescription order, date of transmis-
sion by the interim storage device, and
identity of the recipient of such transmis-
sion. The interim storage device must be
maintained to prevent unauthorized ac-
cess and use of prescription information,
including dispensing information. The
proposed language would also require any
person who transmits, maintains, or re-
ceives any prescription or prescription re-
fill, orally, in writing, or electronically, to
ensure the security, integrity, and confi-
dentiality of the prescription and any in-
formation contained therein. The Board
agreed to pursue this regulatory language;
at this writing, however, notice of the
Board's intent to adopt this proposal has
not been published in the California Reg-
ulatory Notice Register.
Also at its May meeting, the Board
noted that state and federal law may con-
flict on the issue of the electronic trans-
mission of controlled substance prescrip-
tions; the Board asked Deputy Attorney
General William Marcus to analyze cur-
rent law and present his findings to the
Board. At the Board's July meeting, Mar-
cus reported that federal law and state law
are not currently consistent. In general,
federal statutes and regulations require
that a Schedule II prescription must be in
writing and personally signed by the pre-
scriber, except in an emergency. However,
recent amendments to federal regulations,
effective May 19, 1994, authorize the use
of facsimile prescriptions for Schedule II
controlled substances, provided the origi-
nal written prescription is presented be-
fore the prescription is actually dispensed;
those amendments also authorize the use
of a facsimile prescription in lieu of a
written prescription for home infusion/IV
therapy for patients at home, in a hospice,
or at a long-term care facility, or for pa-
tients in long-term care facilities where the
drugs are delivered to the facility. Accord-
ing to Marcus, federal regulations do not
currently recognize data electronic trans-
missions of Schedule II prescriptions, and
do not authorize an oral prescription for a
Schedule II substance except in an emer-
gency.
Marcus further noted that California law
generally requires a Schedule II prescription
to be written on a triplicate form, except in
an emergency or for patients of certain facil-
ities under AB 1807. In an emergency, Cal-
ifornia law authorizes the use of an oral or
electronically transmitted prescription in lieu
of a physician's triplicate; alternatively, the
physician may issue a written prescription
on a non-triplicate form in an emergency.
In either case, the pharmacist must reduce
the prescription to writing and the physi-
cian must, within 72 hours, issue the usual
triplicate to cover the drugs dispensed on
an emergency basis. Also, as noted above,
California law now authorizes an order for
a Schedule II drug in a licensed skilled
nursing facility, an intermediate care facil-
ity, or a licensed home health agency pro-
viding hospice care to be dispensed upon
either an oral or electronically transmitted
prescription, provided that it is reduced to
writing on a pharmacy triplicate prior to
dispensing; the physician need not sign
this form, although the facility is required
to provide the pharmacy with a copy of the
original order.
At the July meeting, the Board dis-
cussed Marcus' findings, and raised addi-
tional questions stemming from the incon-
sistencies between federal and state law in
this area; the Board will continue to ad-
dress this matter at a future meeting.
Automation of the Triplicate Program.
At its May 25-26 meeting, the Board agreed
to contribute $136,506 to fund a study to
develop a model for automating the tripli-
cate prescription program for controlled
substances. California law currently re-
quires that Schedule 11 prescriptions be
ordered on a triplicate form; the goal of the
study is to identify a way to implement an
automated statewide monitoring system
for tracking controlled substances in order
to replace and modernize the current
paper-intensive triplicate system. At the
meeting, Medical Board of California
(MBC) Executive Director Dixon Arnett
announced that MBC would contribute at
least one-quarter of the study's cost; other
interested boards are expected to eventu-
ally contribute to the cost as well.
At its May meeting, the Board also de-
cided to form a steering committee to over-
see the study; that committee held its first
meeting on July 18. At the Board's July 29
meeting, Committee Chair Kent Wilcox re-
ported on the study's progress; among other
things, Wilcox estimated that the study
would be complete by December 1.
Oral Consultation Regulations. At
its July 28 meeting, the Board held a pub-
lic hearing on its proposed amendments to
section 1707.2, Title 16 of the CCR, which
would apply the same requirements or
standards for oral consultation to out-of-
state pharmacies that ship, mail, or deliver
prescriptions as are applied to in-state
pharmacies. As proposed, the rule would
provide that any resident or non-resident
pharmacy that ships, mails, or delivers any
controlled substances or dangerous drugs
or devices shall make a reasonable attempt
to contact the patient or his/her agent and
provide oral consultation over the tele-
phone. If the pharmacy is unable to pro-
vide oral consultation and further attempts
would result in unnecessary delay in the
patient receiving the medication, then the
pharmacy shall document the attempts
made to contact the patient or agent; en-
sure that the patient receives written notice
of his/her right to consultation; provide
the patient or agent with a written consul-
tation that includes directions for use and
storage and any precautions and relevant
warnings; and provide written notice of a
telephone number from which the patient
may obtain oral consultation. [14:2&3
CRLR 95]
At the hearing, the Board considered
comments received during the 45-day
comment period as well as oral testimony
and several articles discussing the matter.
Those in favor of the regulation stated that
standards of practice should be uniform
wherever pharmacy is practiced and that
the interests of patients are better served
when they are informed about their pre-
scriptions. Opponents argued that the reg-
ulation would impose unnecessary costs
on mail order pharmacies without achiev-
ing much benefit, reduce the cost-effec-
tiveness of mail order pharmacies by in-
creasing costs to consumers, possibly
compromise patient confidentiality, and
excessively impact interstate commerce.
Following the discussion, the Board
modified the proposed language to require
that pharmacies make a reasonable attempt
to contact the patient or patient's agent and
provide oral consultation within twelve
hours of anticipated receipt of the prescrip-
tion. The modifications also define the terms
"reasonable attempt," "patient's agent," "an-
cillary staff," and "automated dialing de-
vice"; permit ancillary staff or an automatic
dialing device to initiate the telephone
call, provided that the patient is clearly
advised that a pharmacist is available to
provide oral consultation; and require that
all documentation of consultation and at-
tempts to provide consultation be main-
tained and accessible for three years and
provided to the Board upon request. The
Board adopted the changes subject to
these modifications, and released the re-
90 California Regulatory Law Reporter - Vol. 14, No. 4 (Fall 1994)
REGULATORY AGENCY ACTION
vised text for an additional 15-day com-
ment period which ended on August 25.
At this writing, the Board is scheduled to
consider any new comments received dur-
ing the comment period and to make any
other necessary adjustments at its October
meeting.
At its May and July meetings, the Board
heard reports regarding the enforcement
of its oral consultation regulations by
Board inspectors. [14:2&3 CRLR 94-95]
Board member Raffi Simonian explained
that Board inspectors simply observe what
is occurring in the pharmacy during in-
spections; if the pharmacist does not di-
rectly communicate with the patient when
required, the pharmacist receives a viola-
tion notice. The Board will continue to
hear reports on the enforcement of its oral
consultation regulations at future meet-
ings in order to ensure compliance.
Kaiser's Shot Card Policy. Also at the
May meeting, the Board heard a presenta-
tion from the Kaiser Permanente Group
regarding its shot card policy and modifi-
cations thereto made in response to a pa-
tient complaint lodged earlier this year.
Shot cards are orders for injections, issued
by a primary care physician, that may be
used at various locations of the same
health care entity; under a shot card pro-
gram, a patient may receive injections
from a registered nurse when needed. The
modifications were spurred by a medical
malpractice complaint against Kaiser in
which the patient complained that she be-
came addicted to Demerol by repeatedly
using the shot card in her possession. The
patient was often able to get more than six
shots in six days of potent painkillers. In
addition to making internal modifications
to its shot card program, Kaiser also par-
ticipated with the Medical Board, the At-
tomey General's Office, and the Board of
Pharmacy in drafting legislation to require
health care facilities to implement more
stringent protocols and procedures when
administering dangerous drugs via a shot
card system (see LEGISLATION for a
summary of AB 3260).
Kaiser's representatives described some
of the changes and new strategies being
pursued in its facilities to better protect pa-
tients and prevent possible abuse of the sys-
tem. According to Kaiser, its policy is to
minimize the use of shot cards; it now pro-
hibits multiple injections via a single shot
card, prohibits patients from personally
transmitting a shot card order, and requires
close monitoring of patient and drug records.
Also, its existing immunization tracking
system is being modified to become the
core of a regionwide computerized master
file to track injections and Kaiser is im-
plementing a pilot program to test the sys-
tem; the system would permit physicians
throughout the region to access patient
drug profiles. The Board stated that the
new system is an improvement and noted
that shot card programs must be carefully
administered and monitored.
Rulemaking Update. The following
is a status report on Board rulemaking
proposals discussed in previous issues of
the Reporter:
- At its May 26 meeting, the Board
modified and adopted proposed new sec-
tions 1751.11 and 1751.12, Title 16 of the
CCR. Section 1751.11 would establish a
list of dangerous drugs which may be fur-
nished by a pharmacist to a home health
agency or licensed hospice and stored in
transportable, tamper-proof, sealed stor-
age containers, and create inventory and
recordkeeping requirements for the phar-
macy and home health agency or licensed
hospice. Section 1751.12 would provide
that a pharmacy shall not issue portable
containers unless the home health agency
or licensed hospice complies with the pro-
visions of section 1751.11. [14:2&3 CRLR
95-96; 14:1 CRLR 73; 13:4 CRLR 82] The
Board modified proposed section 1751.11
by increasing the allowable amounts of
0.9% sodium chloride and 5% dextrose in
water injection from 500 milliliters to
1,000 milliliters. In late June, the Board
released the modified language for the
required 15-day comment period; at this
writing, the rulemaking file awaits ap-
proval by the Department of Consumer
Affairs (DCA) and the Office of Adminis-
trative Law (OAL).
- On May 26, the Board held a public
hearing on its proposed amendments to
section 1724, Title 16 of the CCR, which
would provide that the California pharma-
cist licensure examination consists of two
sections, one multiple choice and one
essay, both of which must be passed; any
candidate failing the multiple choiae sec-
tion shall be given a failing grade for the
entire exam without regard to the essay
section. As a result, candidates who fail
the multiple choice section will not re-
ceive a score for the essay section and will
be required to take the entire exam again.
The purpose of this change is to streamline
the examination and grading process by
reducing the time and cost for expert grad-
ers and related travel expenses. Currently,
the regulation provides that a candidate
must achieve a score of 75 or more on each
section of the exam, and that a candidate
who receives less than 75 on one section
may retake that one section only at the
next scheduled examination. [14:2&3
CRLR 96; 14:1 CRLR 74]
At the hearing, the Board heard testi-
mony from Dr. John Cronin of the Califor-
nia Pharmacists Association (CPhA) on
behalf of pharmacy student members of
the CPhA who were concerned about the
regulation. The Board also discussed the
value of giving a diagnostic report to the
candidate in addition to a score, a provi-
sion that was not included in the language
of the regulation but was mentioned in the
Board's initial statement of reasons. After
discussion, the Board adopted a revised
version of the proposed regulation; as
modified, section 1724 would provide that
a score of 75 or more on both sections is
required to pass the exam, and that a can-
didate who fails the multiple-choice sec-
tion will be given a failing grade for the
entire exam. The Board also determined
that a diagnostic report will not be pro-
vided to an applicant. In late June, the
Board released the modified language for
the required 15-day comment period; at
this writing, staff is preparing the rulemak-
ing file for submission to DCA and OAL
for review and approval.
- At its May 26 meeting, the Board
again discussed its proposed citation and
fine regulations; among other things, the
proposed regulations would authorize the
Executive Officer, a Board committee,
and the Board's Northern and Southern
Interim Committees to issue citations and
fines. Following the Board's March meet-
ing, at which time the Board unanimously
agreed to the concept of a citation and fine
program, the Board released the proposed
language for an additional 15-day public
comment period. [14:2&3 CRLR 95; 14:1
CRLR 73] At its May meeting, the Board
heard testimony from representatives of
the California Retailers Association's
chain drug committee, who were critical
of the proposed program. The Board also
discussed the possibility of a written ap-
peals process that would not require a
licensee to take time off from work to
appear before a committee; the effective-
ness of using an appearance before a com-
mittee as a form of discipline; the possi-
bility that pharmacists may refuse to pay
a fine and appeal the decision, thereby
causing greater delays; and the need to
allow for extenuating circumstances which
may affect compliance. The Board also
discussed the probable benefits of the pro-
gram, such as easier detection of fraudu-
lent activity, the ability to discipline unli-
censed individuals, an increased aware-
ness regarding the seriousness of viola-
tions, and providing a means of cost re-
covery for inspectors' time through fines.
Following discussion, the Board rejected
the citation and fine program as proposed
and established a committee to review the
program in order to determine its neces-
sity.
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At its July 28 meeting, the Board con-
tinued its discussion, with some Board
members expressing reservations about
implementing a broad citation and fine
program; instead, those members felt that
the Board's citation and fine program
should take a more narrow focus. Follow-
ing discussion, the Board unanimously
agreed to establish a citation and fine pro-
gram that would authorize inspectors to
cite and fine for unlicensed activity and for
violations of the Board's oral consultation
regulations; at this writing, notice of the
new proposed language has not yet been
published in the California Regulatory
Notice Register.
U LEGISLATION
SB 2101 (McCorquodale), as amended
July 7, revises the requirements for re-
newal of a pharmacist's license. This bill
was signed by the Governor on September
30 (Chapter 1275, Statutes of 1994).
AB 3260 (Bornstein), as amended Au-
gust 24, authorizes health facilities, as de-
fined, to establish and maintain injection
card systems ("shot cards") for controlled
substances that allow an outpatient to re-
ceive injections at the facility pursuant to
a prior written order by a physician. It
requires such facilities to develop a writ-
ten protocol including certain information
regarding the use of the injection card
system prior to its implementation (see
MAJOR PROJECTS). This bill was signed
by the Governor on September 19 (Chap-
ter 653, Statutes of 1994).
The following is a status update on
bills reported in detail in CRLR Vol. 14,
Nos. 2 & 3 (Spring/Summer 1994) at pages
96-98:
SB 2036 (McCorquodale), as amended
August 26, creates a "sunset" review pro-
cess for occupational licensing boards
within DCA, requiring each to be compre-
hensively reviewed every four years. SB
2036 imposes an initial "sunset" date of
July 1, 1998 for the Board; creates a Joint
Legislative Sunset Review Committee
which will review the Board's perfor-
mance approximately one year prior to its
sunset date; and specifies II categories of
criteria under which the Board's perfor-
mance will be evaluated. Following re-
view of the agency and a public hearing,
the Committee will make recommenda-
tions to the legislature on whether the
Board should be abolished, restructured,
or redirected in terms of its statutory au-
thority and priorities. The legislature may
then either allow the sunset date to pass (in
which case the Board would cease to exist
and its powers and duties would transfer
to DCA) or pass legislation extending the
sunset date for another four years. This bill
was signed by the Governor on September
26 (Chapter 908, Statutes of 1994).
AB 2973 (Aguiar), as amended Au-
gust 25, would have created a new certifi-
cation program within the Board to regu-
late "veterinary food-animal retailers,"
defined as a place, other than a pharmacy,
that holds a valid wholesaler certificate,
license, permit, or registration, from which
veterinary drugs for food-producing ani-
mals are dispensed pursuant to a prescrip-
tion from a licensed veterinarian, and which
is issued a permit for that location by the
Board. Governor Wilson vetoed this bill
on September 30. According to Wilson,
the new licensure program should be self-
suppoqting through the imposition of li-
censure and renewal fees; under the bill as
written, Wilson contended that the esti-
mated revenue that would be generated by
those fees is substantially less than the
costs associated with implementing the
program.
AB 3173 (Snyder). Existing law per-
mits pharmacists practicing in hospitals to
perform four specified functions which
may not be performed by pharmacists in
non-hospital settings. As amended August
23, this bill would have provided that
these four functions may also be per-
formed by pharmacists as part of the care
provided by certain unlicensed facilities
operated by a health care service plan, or
by a licensed clinic, a home health agency,
or a provider who contracts with a licensed
health care service plan in accordance
with policies, procedures, or protocols of
that facility, clinic, home health agency, or
health care service plan developed by
health professionals. Under the bill, the
policies, procedures, or protocols must re-
quire that pharmacists may perform these
functions only as part of a multidiscipli-
nary group that includes physicians and
surgeons and direct care registered nurses;
and pharmacists who perform these func-
tions must have certain training and expe-
rience prior to performing them. On Sep-
tember 30, Governor Wilson vetoed this
bill, expressing concern over the provi-
sion which permits pharmacists to adjust
a drug therapy in the home. According to
Wilson, the major distinction between a
home and a clinic is the presence of a
physician; although AB 3173 attempted to
ensure quality of care by requiring a phy-
sician to refer each patient to the pharma-
cist, and subjecting all medication man-
agement to physician-approved protocols,
Wilson concluded that "these protocols
cannot substitute for the physician."
SB 1759 (Kopp) is similarto AB 3173,
but omits references to home health agen-
cies (see above). As amended August 23,
this bill provides that a registered pharma-
cist is not prohibited from performing the
four specified functions as part of the care
provided by certain unlicensed facilities
operated by a health care service plan, a
licensed clinic, or a provider who con-
tracts with a licensed health care service
plan, in accordance with policies, proce-
dures, or protocols of that facility, clinic,
or health care service plan developed by
health professionals, provided that the
pharmacist has successfully completed
clinical residency training or demon-
strated clinical experience in direct patient
care delivery. It requires that these poli-
cies, procedures, or protocols include re-
quirements that the medical records of the
patient be available to both the patient's
prescriber and the licensed pharmacist,
that the procedures to be performed by a
licensed physician relate to a condition for
which the patient has already seen a phy-
sician, and that in certain instances the
pharmacist function as part of a multidis-
ciplinary group that includes physicians
and direct care registered nurses. This bill
was signed by the Governor on September
29 (Chapter 1161, Statutes of 1994).
AB 3388 (Harvey). Existing law pro-
vides that no provision of law shall be
construed to prohibit a pharmacy from
furnishing a prescription drug or device to
a licensed health care facility for storage
in a prescribed manner. As amended Au-
gust 18, this bill requires that these sup-
plies furnished by a pharmacy to licensed
health facilities for storage in a prescribed
manner be approved by the facility's pa-
tient care policy committee or pharmaceu-
tical service committee and be readily avail-
able to each nursing station. Notwithstand-
ing the Department of Health Services'
(DHS) regulation at section 72377, Title 22
of the CCR, the bill provides that a total
of 24 oral dosage form or suppository
form drugs may be furnished by a phar-
macy to certain health facilities as de-
scribed above and provides that DHS may
limit the number of doses of any separate
drug dosage form in each emergency sup-
ply to four. [14:2&3 CRLR 98; 14:1 CRLR
75] This bill was signed by the Governor
on September 28 (Chapter 1060, Statutes
of 1994).
SB 1364 (Marks). Under existing law,
controlled substances that are classified as
Schedule I substances are not authorized
to be used for legitimate medical pur-
poses. As introduced February 1, this bill
would have made legislative findings and
declarations and provided that marijuana
is deemed a Schedule II substance for use
for legitimate medical purposes. This bill
was vetoed by Governor Wilson on Sep-
tember 30; according to Wilson, the pro-
visions of SB 1427 are preempted by fed-
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eral controlled substances law, which pro-
hibits the use of marijuana for medical
reasons.
SB 1427 (Mello). Existing law autho-
rizes a pharmacist, when filling a prescrip-
tion drug order, to select another drug
product with the same active chemical
ingredients of the same strength, quantity,
and dosage form, and of the same generic
drug type, as defined, under certain cir-
cumstances. As amended May 16, this bill
would have defined the term "dosage
form" and authorized a pharmacist-not-
withstanding that definition and except
when the prescriber indicates no substitu-
tions may be made-to substitute one
drug product for another drug product if
the drug products are classified as both
pharmaceutically equivalent and thera-
peutically equivalent in the U.S. Food and
Drug Administration's Approved Drug
Products with Therapeutic Equivalence
Evaluations. This bill was vetoed by Gov-
ernor Wilson on September 15. According
to Wilson, SB 1427 would have the prac-
tical effect of precluding pharmacists from
substituting drugs that utilize different de-
livery mechanisms, even if such drugs
have identical therapeutic outcomes; Wil-
son opined that such a result would in-
crease the costs of drug prescriptions.
SB 1642 (Craven), as amended Au-
gust 11, authorizes a licensed physician
approved to supervise a physician assis-
tant (PA) to delegate to a PA under his/her
supervision, and in a manner determined
by the supervising physician (SP), the au-
thority to administer or provide medica-
tion to a patient or transmit a prescription
from the SP to a person who may lawfully
furnish the medication or medical device
to the patient. It requires the SP, prior to
delegating prescription transmittal author-
ity to a PA, to adopt a written, practice-
specific formulary and protocols that
specify all criteria to be considered for use
of a particular drug or device, and any
contraindications for the drug or device.
The bill requires any SP's prescription that
is transmitted by the PA to be based on
either the physician's order for the partic-
ular patient or for a drug listed in the
formulary. It prohibits a PA from adminis-
tering, providing, or transmitting a pre-
scription for Schedule II through Schedule
V controlled substances without an order
from the SP. The bill imposes other re-
quirements regarding the content of the
prescription transmittal order. It provides
that when transmitting a prescription the
PA is acting on behalf of and as an agent
for the SP.
Existing law authorizes a licensed
pharmacist to dispense drugs or devices
upon the order of a nurse practitioner with
certain authority. This bill authorizes a
licensed pharmacist to also dispense drugs
or devices upon a transmittal order of a PA
with certain authority. This bill was signed
by the Governor on September 27 (Chap-
ter 968, Statutes of 1994).
AB 2610 (Bronshvag), as amended
May 27, would have established the Clean
Needle and Syringe Exchange Program,
and authorized pharmacists, physicians,
and certain persons authorized under the
pilot project to furnish hypodermic nee-
dles and syringes without a prescription or
permit as prescribed through the program.
On September 30, Governor Wilson ve-
toed this bill, questioning whether it is
"worth reducing the risk of infection to
intravenous drug users at the potential for
greater cost of undermining all other pre-
ventive anti-drug efforts and suffering as
a result an enormous increase in the num-
ber of young people who make a wrong
choice that leads to an enormous increase
in addicts."
SB 849 (Bergeson). Under the Phar-
macy Law, a "hospital pharmacy" means
and includes a pharmacy licensed by the
Board of Pharmacy located within any
hospital, institution, or establishment that
maintains and operates organized inpa-
tient facilities for the diagnosis, care, and
treatment of human illnesses in accor-
dance with certain requirements. Existing
law requires DHS to issue a single consol-
idated license to a general acute care hos-
pital that meets certain requirements. As
amended May 11, this bill permits, under
certain conditions, a hospital pharmacy to
be located outside of the hospital in a
physical plant that is regulated under a
hospital's consolidated license. This bill
was signed by the Governor on July 15
(Chapter 218, Statutes of 1994).
The following bills died in committee:
SB 2045 (Petris), which would have spec-
ified that a pharmacist is liable to a parent,
guardian, or other legal custodian of a
patient under the age of 14 years, if the
pharmacist knows, or should know, this
fact and the fact that the medication is to
be administered by the parent, guardian,
or other legal custodian and mislabels the
dosage of a prescription medication or
otherwise incorrectly fills or mislabels a
prescription; SB 2087 (Mello), which
would have repealed a requirement that
the Board adopt regulations that apply the
same requirements or standards for oral
consultation to an out-of-state pharmacy
that ships, mails, or delivers controlled
substances or dangerous drugs or devices
to a resident of this state, as are applied to
an in-state pharmacy when the pharmacy
ships, mails, or delivers any controlled
substances or dangerous drugs or devices
to a resident of this state, and instead re-
quired any pharmacy, whether located in
this state or outside this state, that ships,
mails, or delivers a prescription medica-
tion to a resident of this state to provide a
toll-free telephone service during normal
business hours for patients to receive oral
consultation from a pharmacist who has
access to the patient's records; SB 1048
(Watson), which would have established
the Clean Needle and Syringe Exchange
Pilot Project, and authorized pharmacists,
physicians, and certain other persons to
furnish hypodermic needles and syringes
without a prescription or permit as pre-
scribed through the pilot project; and AB
2020 (Isenberg), which would have,
among other things, authorized optome-
trists to use, prescribe, and dispense spec-
ified pharmaceutical compounds to a pa-
tient.
* RECENT MEETINGS
At its May 25-26 meeting, the Board
worked with facilitator Michael Dues to
plan new strategies for the Board's future.
The planning session produced a mission
statement that describes the duties of the
Board, a vision statement that defines the
stakeholders in the Board's actions, and a
set of "headlines" that reflect the Board's
general goals.
Also at its May meeting, the Board
heard a request from Dr. Eileen Goodis,
president of Patient Care Pharmacy, for
approval to perform a study with the USC
School of Pharmacy on the use of an au-
tomated dispensing machine in long-term
care settings; the goal of the study is to
improve the delivery of medications in the
long-term care setting while providing ad-
equate review by a pharmacist. The Board
determined that the matter falls under
DHS' jurisdiction; however, the Board
agreed to write a letter to DHS supporting
and requesting approval for the study.
Also at its May meeting, the Board
elected Janeen McBride to serve as Presi-
dent, Marilyn Shreve to serve as Vice-
President, and Kent Wilcox to serve as
Treasurer. The Board also created the of-
fice of parliamentarian, to be filled by the
outgoing Board President.
At its July 27-28 meeting, the Board
discussed the issue of prescription drug
sample distribution in order to compare
federal and California law on the issue.
Deputy Attorney General William Marcus
submitted an analysis which determined
that state and federal law permits samples
to be furnished to a hospital pharmacy or
other health care entity by a drug manu-
facturer only at the written request of a
licensed practitioner and according to spe-
cific distribution requirements. Federal
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law goes further, however, to establish
additional requirements for storage, distri-
bution, and annual audits; there are also
pending changes in federal statutes and
regulations that would ban the practice of
furnishing samples to physicians and
other health care providers and restrict a
community pharmacy from possessing
drug samples. The Board agreed to con-
tinue its discussion of this topic at a future
meeting.
Also in July, the Board approved a
budget change proposal to finance a pub-
lic education program to inform consum-
ers about the benefits associated with the
new oral consultation opportunity. The
Board hopes to reach consumers about the
pharmacist consultation program through
editorials, television and radio announce-
ments, and by serving as a resource to
statewide media.
0 FUTURE MEETINGS
October 24-25 in Sacramento.
January 25-26, 1995 in Los Angeles.
March 29-30, 1995 in Sacramento.
May 24-25, 1995 in Sacramento.
July 26-27, 1995 in San Diego.









T he Board of Registration for Profes-
sional Engineers and Land Surveyors
(PELS) regulates the practice of engineer-
ing and land surveying through its admin-
istration of the Professional Engineers Act,
sections 6700 through 6799 of the Busi-
ness and Professions Code, and the Pro-
fessional Land Surveyors Act, sections
8700 through 8806 of the Business and
Professions Code. The Board's regula-
tions are found in Division 5, Title 16 of
the California Code of Regulations (CCR),
sections 400 through 471.
The basic functions of the Board are to
conduct examinations, issue certificates,
registrations, and/or licenses, and appro-
priately channel complaints against regis-
trants/licensees. The Board is additionally
empowered to suspend or revoke registra-
tions/licenses. The Board considers the
proposed decisions of administrative law
judges who hear appeals of applicants who
are denied a registration/license, and those
who have had their registration/license
suspended or revoked for violations.
The Board consists of thirteen mem-
bers: seven public members, one licensed
land surveyor, four registered Practice Act
engineers and one Title Act engineer. The
Governor appoints eleven of the members
for four-year terms that expire on a stag-
gered basis. Additionally, both the Assem-
bly Speaker and the Senate Rules Com-
mittee appoint one public member each.
The Board has established four stand-
ing committees and appoints other special
committees as needed. The four standing
committees are Administration, Enforce-
ment, Examination/Qualifications, and
Legislation. Committees function in an
advisory capacity unless specifically au-
thorized by the Board to make binding
decisions.
Professional engineers are registered
through the three Practice Act categories
of civil, electrical, and mechanical engi-
neering under section 6730 of the Busi-
ness and Professions Code. Land survey-
ors, another Practice Act category, are reg-
istered through section 8725 of the Busi-
ness and Professions Code. The Title Act
categories of agricultural, chemical, con-
trol system, corrosion, fire protection, in-
dustrial, manufacturing, metallurgical,
nuclear, petroleum, quality, safety, and
traffic engineering are registered under
section 6732 of the Business and Profes-
sions Code.
Structural engineering and geotechni-
cal engineering are "title authorities" linked
to the civil Practice Act and require an
additional examination after qualification
as a civil engineer.
During the summer, Governor Wilson
appointed public members Eugenie
Thomson and Chip Mamiya to the Board.
Thomson is president of Thomson Trans-
portation Engineers, Inc. in Alameda, and
Mamiya is regional sales manager of Bar-
clays American Mortgage Corporation in
Los Angeles. They attended their first
Board meetings on July 8 and August 19,
respectively.
U MAJOR PROJECTS
Strategic Planning Process Update.
In response to criticism levied at PELS
during the November 1993 oversight hear-
ing conducted by the Senate Subcommit-
tee on Efficiency and Effectiveness in State
Boards and Commissions, the Board has
been formulating a "strategic plan" de-
signed to clarify its role, functions, and
constituencies. [14:2&3 CRLR 99] To that
end, PELS adopted the following mission
statement at its June 17 meeting: "The
mission of the Board of Registration for
Professional Engineers and Land Survey-
ors is to safeguard the life, health, prop-
erty, and public welfare by regulating the
practice of professional engineering and
professional land surveying. We qualify
and license individuals; establish regula-
tions; enforce laws and regulations; [and]
provide information so that the public can
make informed decisions." PELS also
adopted a "vision statement" of its future
goals, which states as follows: PELS as-
sures that qualified applicants are licensed
as quickly as possible; registrants main-
tain continuing competency; disputes are
resolved for consumers and registrants
promptly and impartially; adequate infor-
mation is available to all through a high-
profile comprehensive information pro-
gram; violations of the law are discour-
aged before they happen and are investi-
gated and adjudicated promptly when
committed; the Board is managed strate-
gically and its budget is performance-
based; legislative changes are approached
proactively; its performance is measured
against defined standards and it periodi-
cally evaluates its programs and policies
in light of emerging trends, practices, and
technologies; the professional engineer-
ing and professional land surveying laws
and regulations are clear, relevant, unam-
biguous, and functional; and PELS at-
tracts highly competent staff who contrib-
ute to the integral success of the Board,
and maintains a work environment where
employees are satisfied and productive
because they feel valued and challenged.
Also at its June meeting, the Board
approved a preliminary schedule to adopt
the final version of its strategic plan by
March 1995; the strategic plan will lay out
a process that identifies issues and major
activities and directs them to the appropri-
ate standing Board committees for further
investigation. At its September 9 meeting,
PELS established the following issues and
major activities to be explored in conjunc-
tion with the formulation of the strategic
plan: operational support systems, regula-
tion modernization, consumer and public
communications, emergency prepared-
ness, mechanized testing, code of ethics,
continuing competency, and the North
American Free Trade Agreement. The
Board directed its various committees to
discuss the topics applicable to them, and
submit an analysis of each topic for use in
the strategic plan at PELS' November 18
meeting.
One major goal which the Board hopes
to accomplish through its strategic plan-
ning process is a comprehensive overhaul
of the Professional Engineers Act, the
Board's regulations in Title 16 of the CCR,
and the way the state of California licenses
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